Diabetes & Metabolism Journal

Sulwon Lecture 2022

Others
Opening the Precision Diabetes Care through Digital Healthcare: Joonyub Lee, Jin Yu, Kun-Ho Yoon; Diabetes Metab J. 2023;47(3):307-314. Published online March 29, 2023; DOI: https://doi.org/10.4093/dmj.2022.0386

5,260 View
247 Download

Abstract PDF PubReader ePub: The national healthcare systems of every country in the world cannot sustain the rise in healthcare expenditure caused by chronic diseases and their complications. To sustain the national healthcare system, a novel system should be developed to improve the quality of care and minimize healthcare costs. For 20 years, our team developed patient-communicating digital healthcare platforms and proved their efficacy. National scale randomized control trials are underway to systematically measure the efficacy and economic benefits of this digital health care system. Precision medicine aims to maximize effectiveness of disease management by considering individual variability. Digital health technologies enable precision medicine at a reasonable cost that was not available before. The government launched the “National Integrated Bio-big Data Project” which will collect diverse health data from the participants. Individuals will share their health information to physicians or researchers at their will by gateway named “My-Healthway.’ Taken together, now we stand in front of the evolution of medical care, so-called “Precision medicine.” led by various kinds of technologies and a huge amount of health information exchange. We should lead these new trends as pioneers, not as followers, to establish and implement the best care for our patients that can help them to withstand their devastating diseases.

Reviews

Drug/Regimen
Evaluating the Evidence behind the Novel Strategy of Early Combination from Vision to Implementation: Päivi Maria Paldánius; Diabetes Metab J. 2020;44(6):785-801. Published online September 15, 2020; DOI: https://doi.org/10.4093/dmj.2020.0179

7,109 View
287 Download

Abstract PDF PubReader ePub: Type 2 diabetes mellitus (T2DM) is a complex and progressive chronic disease characterised by elevating hyperglycaemia and associated need to gradually intensify therapy in order to achieve and maintain glycaemic control. Treating hyperglycaemia with sequential therapy is proposed to allow holistic assessment of the efficacy and risk-to-benefit ratio of each added component. However, there is an array of evidence supporting the scientific rationale for using synergistic, earlier, modern drug combinations to achieve glycaemic goals, delay the deterioration of glycaemic control, and, therefore, potentially preserve or slow down the declining β-cell function. Additionally, implementation of early combination(s) may lead to opportunities to combat clinical inertia and other hurdles to optimised disease management outcomes. This review aims to discuss the latest empirical evidence for long-term clinical benefits of this novel strategy of early combination in people with newly diagnosed T2DM versus the current widely-implemented treatment paradigm, which focuses on control of hyperglycaemia using lifestyle interventions followed by sequentially intensified (mostly metformin-based) monotherapy. The recent reported Vildagliptin Efficacy in combination with metfoRmin For earlY treatment of T2DM (VERIFY) study results have provided significant new evidence confirming long-term glycaemic durability and tolerability of a specific early combination in the management of newly diagnosed, treatment-naïve patients worldwide. These results have also contributed to changes in clinical treatment guidelines and standards of care while clinical implementation and individualised treatment decisions based on VERIFY results might face barriers beyond the existing scientific evidence.

Basic Research
Histone Deacetylase 9: Its Role in the Pathogenesis of Diabetes and Other Chronic Diseases: Siqi Hu, Eun-Hee Cho, Ji-Young Lee; Diabetes Metab J. 2020;44(2):234-244. Published online March 24, 2020; DOI: https://doi.org/10.4093/dmj.2019.0243

6,369 View
161 Download
20 Web of Science
21 Crossref

Abstract PDF PubReader

As a member of the class IIa histone deacetylases (HDACs), HDAC9 catalyzes the deacetylation of histones and transcription factors, commonly leading to the suppression of gene transcription. The activity of HDAC9 is regulated transcriptionally and post-translationally. HDAC9 is known to play an essential role in regulating myocyte and adipocyte differentiation and cardiac muscle development. Also, recent studies have suggested that HDAC9 is involved in the pathogenesis of chronic diseases, including cardiovascular diseases, osteoporosis, autoimmune disease, cancer, obesity, insulin resistance, and liver fibrosis. HDAC9 modulates the expression of genes related to the pathogenesis of chronic diseases by altering chromatin structure in their promotor region or reducing the transcriptional activity of their respective transcription factors. This review summarizes the current knowledge of the regulation of HDAC9 expression and activity. Also, the roles of HDAC9 in the pathogenesis of chronic diseases are discussed, along with potential underlying mechanisms.

Citations

Citations to this article as recorded by

Impact of housing temperature on adipose tissue HDAC9 expression and adipogenic differentiation in high fat‐fed mice
Samah Ahmadieh, Brandee Goo, Abdalrahman Zarzour, David Kim, Hong Shi, Praneet Veerapaneni, Ronnie Chouhaita, Nicole K. H. Yiew, Carla Dominguez Gonzalez, Akash Chakravartty, James Pennoyer, Nazeera Hassan, Tyler W. Benson, Mourad Ogbi, David J. Fulton, R
Obesity.2024; 32(1): 107. CrossRef
HDAC9 inhibition reduces skeletal muscle atrophy and enhances regeneration in mice with cigarette smoke-induced COPD
Guixian Zheng, Chao Li, Xiaoli Chen, Zhaohui Deng, Ting Xie, Zengyu Huo, Xinyan Wei, Yanbing Huang, Xia Zeng, Yu Luo, Jing Bai
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2024; 1870(3): 167023. CrossRef
Identification of HDAC9 and ARRDC4 as potential biomarkers and targets for treatment of type 2 diabetes
Jing Liu, Lingzhen Meng, Zhihong Liu, Ming Lu, Ruiying Wang
Scientific Reports.2024;[Epub] CrossRef
HDAC9 as a Privileged Target: Reviewing its Role in Different Diseases and Structure-activity Relationships (SARs) of its Inhibitors
Totan Das, Samima Khatun, Tarun Jha, Shovanlal Gayen
Mini-Reviews in Medicinal Chemistry.2024; 24(7): 767. CrossRef
Targeting histone deacetylases for cancer therapy: Trends and challenges
Tao Liang, Fengli Wang, Reham M. Elhassan, Yongmei Cheng, Xiaolei Tang, Wengang Chen, Hao Fang, Xuben Hou
Acta Pharmaceutica Sinica B.2023; 13(6): 2425. CrossRef
Therapeutic approach of natural products that treat osteoporosis by targeting epigenetic modulation
Guokai Zhang, Zhenying Liu, Zihan Li, Bing Zhang, Pengyu Yao, Yun Qiao
Frontiers in Genetics.2023;[Epub] CrossRef
Research Progress on Histone Deacetylase Inhibitors
玉姜汤
Hans Journal of Medicinal Chemistry.2023; 11(02): 116. CrossRef
HDAC9 Inhibition as a Novel Treatment for Stroke
Hugh S. Markus
Stroke.2023; 54(12): 3182. CrossRef
Histone deacetylase 9 exacerbates podocyte injury in hyperhomocysteinemia through epigenetic repression of Klotho
Min Liu, Yang Zhang, Ping Zhan, Wenjuan Sun, Chuanqiao Dong, Xiaohan Liu, Yujie Yang, Xiaojie Wang, Yusheng Xie, Chengjiang Gao, Huili Hu, Benkang Shi, Ziying Wang, Chun Guo, Fan Yi
Pharmacological Research.2023; 198: 107009. CrossRef
Molecular mechanism and therapeutic potential of HDAC9 in intervertebral disc degeneration
Ming Lei, Hui Lin, Deyao Shi, Pan Hong, Hui Song, Bomansaan Herman, Zhiwei Liao, Cao Yang
Cellular & Molecular Biology Letters.2023;[Epub] CrossRef
Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A
Sylvia Fong, Bridget Yates, Choong-Ryoul Sihn, Aras N. Mattis, Nina Mitchell, Su Liu, Chris B. Russell, Benjamin Kim, Adebayo Lawal, Savita Rangarajan, Will Lester, Stuart Bunting, Glenn F. Pierce, K. John Pasi, Wing Yen Wong
Nature Medicine.2022; 28(4): 789. CrossRef
Active RhoA Exerts an Inhibitory Effect on the Homeostasis and Angiogenic Capacity of Human Endothelial Cells
Michael Hauke, Robert Eckenstaler, Anne Ripperger, Anna Ender, Heike Braun, Ralf A. Benndorf
Journal of the American Heart Association.2022;[Epub] CrossRef
HDAC9 Contributes to Serous Ovarian Cancer Progression through Regulating Epithelial–Mesenchymal Transition
Long Xu, Jian Wang, Buhan Liu, Jiaying Fu, Yuanxin Zhao, Sihang Yu, Luyan Shen, Xiaoyu Yan, Jing Su
Biomedicines.2022; 10(2): 374. CrossRef
Common protein-coding variants influence the racing phenotype in galloping racehorse breeds
Haige Han, Beatrice A. McGivney, Lucy Allen, Dongyi Bai, Leanne R. Corduff, Gantulga Davaakhuu, Jargalsaikhan Davaasambuu, Dulguun Dorjgotov, Thomas J. Hall, Andrew J. Hemmings, Amy R. Holtby, Tuyatsetseg Jambal, Badarch Jargalsaikhan, Uyasakh Jargalsaikh
Communications Biology.2022;[Epub] CrossRef
Proposed minimal essential co-expression and physical interaction networks involved in the development of cognition impairment in human mid and late life
Zahra Salehi, Masoud Arabfard, Omid Sadatpour, Mina Ohadi
Neurological Sciences.2021; 42(3): 951. CrossRef
Emerging roles of SIRT6 in human diseases and its modulators
Gang Liu, Haiying Chen, Hua Liu, Wenbo Zhang, Jia Zhou
Medicinal Research Reviews.2021; 41(2): 1089. CrossRef
Quis Custodiet Ipsos Custodes (Who Controls the Controllers)? Two Decades of Studies on HDAC9
Claudio Brancolini, Eros Di Giorgio, Luigi Formisano, Teresa Gagliano
Life.2021; 11(2): 90. CrossRef
circ_0003204 Regulates Cell Growth, Oxidative Stress, and Inflammation in ox-LDL-Induced Vascular Endothelial Cells via Regulating miR-942-5p/HDAC9 Axis
Huan Wan, Ting You, Wei Luo
Frontiers in Cardiovascular Medicine.2021;[Epub] CrossRef
Histone deacetylase (HDAC) 9: versatile biological functions and emerging roles in human cancer
Chun Yang, Stéphane Croteau, Pierre Hardy
Cellular Oncology.2021; 44(5): 997. CrossRef
Dual HDAC/BRD4 inhibitors against cancer
Negar Omidkhah, Farzin Hadizadeh, Razieh Ghodsi
Medicinal Chemistry Research.2021; 30(10): 1822. CrossRef
miR‐211‐5p is down‐regulated and a prognostic marker in bladder cancer
Weisheng Wang, Zhiming Liu, Xuegang Zhang, Junning Liu, Junqing Gui, Maorong Cui, Yong Li
The Journal of Gene Medicine.2020;[Epub] CrossRef

First
Prev
Page of 1
Next
Last

Search